[Oncoinfo – Istantanee di Oncologia: seguici su [ Ссылка ]] At ASCO 2023 Roy S. Herbst (Yale School of Medicine and Yale Cancer Center) presented the Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).
Ещё видео!